Navigation Links
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
Date:7/14/2014

ensive experience in successfully identifying and bringing oncology treatments to the clinic while Senior Vice President of Research at Cephalon, Inc. (acquired by TEVA Pharmaceuticals). Its Board of Directors includes senior executives in the pharmaceutical industry, with deep mergers and acquisitions (M&A) experience.
  • The company is expected to have steady news flow. Interim Phase II data are expected to be announced at the Apple Congress on Saturday, July 12, 2014. Positive interim data should positively impact the GNSZ stock price. Additionally, in the third quarter the company should initiate Phase II clinical trial in renal cell carcinoma, and in the first quarter of 2015 GenSpera expects to present interim data for ongoing glioblastoma trial.
  • Based on the company's attractive growth prospects with a pipeline of products based upon its unique platform targeting large tumor applications; and strong development and experienced management team that has taken drugs successfully through clinical trials, we recommend the purchase of GNSZ stock for speculative accounts seeking long-term capital appreciation. Our target: more than a double within the next 12-24 months.
  • About GenSpera
    GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

    G-202 Phase II clinical trials are underway
    '/>"/>

    SOURCE GenSpera, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. CVS Caremark Corporation Announces Quarterly Dividend
    2. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
    3. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
    4. Volcano Corporation Announces Preliminary Fourth Quarter 2013 Revenues; Year-Over-Year Annual Revenues Increase Eight Percent On A Constant Currency Basis
    5. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
    6. Heska Corporation to Present at the Sidoti Semi-Annual Micro-Cap Conference
    7. Ramon Martinez Named President of Comprehensive Care Corporation and Elected to the Companys Board of Directors
    8. Dynasil Corporation of America Reports Fiscal Year 2013 Financial Results
    9. Ormco Corporation Files Appeal to the Federal Court Against Ortho Classic H4 Bracket Patent Infringement
    10. EPGL Technology Selected by Major Corporation for Development
    11. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... Ill. , July 31, 2015 ... ® (NABP ® ) issued a report ... ensuring that action is taken against websites illegally ... Internet Drug Outlet Identification Program Progress Report ... , thousands of websites illegally distribute ...
    (Date:7/31/2015)... CHICAGO , July 31, 2015 ... Market by Product (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, ... & End User (Hospitals, Pharmaceuticals) - Global Forecast to 2020", ... reach around USD 6.1 Billion by 2020, at a CAGR ... 242 market data T ables and ...
    (Date:7/31/2015)... 31, 2015  Semler Scientific, Inc. (Nasdaq: SMLR ... to healthcare insurers and physician groups, today reported financial ... "In the second quarter of 2015, ... growth of 54%, quarter over quarter revenue growth of ... base of FloChec® units of 18%," said Doug Murphy-Chutorian, ...
    Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
    ... March 20 Santaris Pharma announced today that,the ... clinic. In the USA,several patients with cancer have ... is jointly developed by Santaris Pharma and Enzon,Pharmaceuticals. ... Enzon Pharma­ceutical,s Investigational New Drug (IND) application,for the ...
    ... REHOVOT, Israel, March 18 XTL Biopharmaceuticals,Ltd. (Nasdaq: ... has entered into an,asset purchase agreement with Bio-GAL Ltd, ... on Recombinant Erythropoietin ("rHuEPO") for the prolongation,of multiple myeloma ... , MM is a severe ...
    Cached Medicine Technology:Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma 2XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma 3
    (Date:8/1/2015)... ... ... and Lita Hart, icons of the network marketing industry and founders of the Healthy ... Movement of EvolvHealth. In what has been a long-term relationship between the companies for ... of purpose together to change the course of the network marketing industry. , “This ...
    (Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to this ... The app is designed to track various metrics of wellness, including physical activity, diet, ... and use this information for positive behavior modification. Lume Wellness keeps track of both ...
    (Date:8/1/2015)... Hartford, CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil ... 2,175 mile trek of the Appalachian Trail by stepping off Springer Mountain and ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
    (Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
    (Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reliable source for authentic tickets ... Grant Park. The festival will end on Sunday, August 2nd. , ... annual Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment ...
    Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2
    ... procedure cuts conception rate, study found , THURSDAY, Oct. ... 15 minutes after being artificially inseminated greatly boost their ... women treated for subfertility with IUI [intrauterine insemination] to ... higher chance at conceiving," said Inge Custers, lead author ...
    ... In ... announced the launch of its online floral gift program, celebrating caregivers who love and ... with aging. , ... Camarillo, California (PRWEB) October 30, 2009 -- In recognition of November,s Alzheimer,s Awareness Month, ...
    ... thrown off schedule by Daylight Saving Time , FRIDAY, ... you,ll get in most parts of the country over the ... Time could spell trouble for your body clock, a sleep ... the sleep disorders research program in the division of sleep ...
    ... led to bigger, healthier infants, studies show , FRIDAY, ... the list of people who should get H1N1 swine ... highlight the benefits of vaccination for moms-to-be and their ... reduced rates of hospitalization top the findings, which are ...
    ... AMERIGROUP Corporation (NYSE: AGP ) today announced that net ... $0.43 per diluted share, versus $37.9 million, or $0.71 per diluted ... are in line with the preliminary earnings range that the Company ... elevated medical costs associated with the onset of what appears to ...
    ... AcelRx Pharmaceuticals, Inc. today announced that it ... the FDA for ARX-01, a drug/device combination product ... which enables delivery of sufentanil by the non-invasive ... alternative to intravenous patient-controlled analgesia (IV PCA) for ...
    Cached Medicine News:Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 2Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18Health News:AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management 2Health News:AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: